Goat Industries Ltd.

Condensed Interim Financial Statements

For the nine months ended September 30, 2025 and 2024

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of Goat Industries Ltd. (the "Company" or "Goat") have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of condensed interim financial statements by an entity's auditor.

Goat Industries Ltd.
Condensed Interim Statement of Financial Position
(Expressed in Canadian Dollars)
(Unaudited – prepared by management)

		September 30, 2025		December 31, 2024 (Audited)
ASSETS				
Current				
Cash	$	91,116	$	887
Loan receivable (Note 5)		415,613		-
Prepaid expenses		8,076		-
		514,805		887
Non-Current				
Investments (Notes 4 and 8)		1		1
TOTAL ASSETS	$	**514,806**	$	888
LIABILITIES AND SHAREHOLDERS' DEFICIENCY				
Current				
Accounts payable and accrued liabilities (Note 9)	$	509,014	$	582,218
Loans payable (Note 6)		166,949		25,000
		675,963		607,218
Non-Current				
Convertible promissory notes (Note 7)		-		224,014
TOTAL LIABILITIES		**675,963**		831,232
SHAREHOLDERS' DEFICIENCY				
Share capital (Note 8)		23,613,816		22,381,949
Subscriptions received in advance (Note 8)		75,000		-
Equity portion of convertible promissory notes (Note 7)		-		44,813
Reserves (Note 8)		2,086,801		1,974,425
Deficit		(25,936,774)		(25,231,531)
TOTAL SHAREHOLDERS' DEFICIENCY		**(161,157)**		(830,344)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY	$	**514,806**	$	888

Nature of operations and going concern (Note 1)
Commitments (Note 11)
Subsequent Events (Note 12)

Approved and authorized for issuance on behalf of the Board on December 1, 2025.

"Justin Jacobson", Director "Lawrence Hay" , Director

(The accompanying notes are an integral part of these condensed interim financial statements)

Goat Industries Ltd.
Condensed Interim Statement of Loss and Comprehensive Loss
(Expressed in Canadian Dollars)
(Unaudited – prepared by management)

		For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Operating Expenses					
Consulting fees		44,230	149,222	112,710	166,470
Foreign exchange		3,958	-	3,958	-
Management fees (Note 9)		3,075	12,525	26,550	36,750
Office and miscellaneous		6,081	24,403	12,881	49,791
Professional fees		47,429	58,295	48,553	68,931
Share based compensation (Notes 8 and 9)		419,795	-	594,795	76,670
Transfer agent and filing fees		11,820	9,758	23,015	23,077
Loss before other income (loss)	$	**(536,388)**	**(254,203)**	**(822,462)**	**(421,689)**
Other income (loss)					
Interest income (Note 5)		3,569	-	3,569	-
Gain (loss) on debt settlement (Note 8)		26,650	-	(60,350)	-
Transaction costs		-	-	(41,000)	(33,500)
Net Loss and Comprehensive Loss for the Period	**$**	**(506,169)**	**$ (254,203)**	**$ (920,243)**	**$ (455,189)**
Net Loss per Share, Basic and Diluted	**$**	**(0.04)**	**$ (0.04)**	**$ (0.08)**	**$ (0.10)**
Weighted Average Number of Shares Outstanding		**13,650,053**	**6,889,974**	**12,061,377**	**4,762,258**

(The accompanying notes are an integral part of these condensed interim financial statements)

Goat Industries Ltd.
Condensed Interim Statement of Changes in Shareholders' Deficiency
(Expressed in Canadian Dollars)
(Unaudited – prepared by management)

	Share Capital #	Share Capital $	Subscriptions Received in Advance $	Equity Portion of Convertible Promissory Notes $	Reserves $	Deficit $	Total $
Balance, December 31, 2023	**3,261,679**	**21,889,909**	**-**	**-**	**1,863,875**	**(24,217,125)**	**(463,341)**
Debt settlement (Note 8)	785,689	76,792	-	-	-	-	76,792
Private placement (Note 8)	3,737,372	331,289	-	-	13,121	-	344,410
Convertible promissory notes (Notes 7 and 8)	-	-	-	54,870	-	-	54,870
Conversion of convertible promissory notes (Note 8)	610,000	58,236	-	(10,057)	-	-	48,179
Share based compensation (Note 8)	-	-	-	-	76,670	-	76,670
Net and comprehensive loss for the period	-	-	-	-	-	(455,189)	(455,189)
Balance, September 30, 2024	**8,394,740**	**22,356,226**	**-**	**44,813**	**1,953,666**	**(24,672,314)**	**(317,609)**
Balance, December 31, 2024	**8,394,740**	**22,381,949**	**-**	**44,813**	**1,974,425**	**(25,231,531)**	**(830,344)**
Debt settlement (Note 8)	600,000	237,000	-	-	-	-	237,000
Conversion of convertible notes (Notes 7 and 8)	2,717,959	270,176	-	(44,813)	-	-	225,363
Exercise of warrants (Note 8)	2,381,810	357,272	-	-	-	-	357,272
Exercise of options (Note 8)	800,000	192,419	-	-	(92,419)	-	100,000
Conversion of RSUs (Note 8)	500,000	175,000	-	-	(175,000)	-	-
Special warrants expired (Note 8)	-	-	-	-	(215,000)	215,000	-
Subscriptions received in advance (Note 8)	-	-	75,000	-	-	-	75,000
Share based compensation (Note 8)	-	-	-	-	594,795	-	594,795
Net and comprehensive loss for the period	-	-	-	-	-	(920,243)	(920,243)
Balance, September 30, 2025	**15,394,509**	**23,613,816**	**75,000**	**-**	**2,086,801**	**(25,936,774)**	**(161,157)**

(The accompanying notes are an integral part of these condensed interim financial statements)

Goat Industries Ltd.
Condensed Interim Statement of Cash Flows
(Expressed in Canadian Dollars)
(Unaudited – prepared by management)

		For the nine months ended September 30, 2025		For the nine months ended September 30, 2024
CASH FLOWS USED IN OPERATING ACTIVITIES				
Net loss for the period	$	(920,243)	$	(455,189)
Items not affecting cash:				
Foreign exchange		3,958		-
Interest income		(3,569)		-
Interest expense		6,298		27,300
Loss on debt settlement		60,350		-
Share based compensation		594,795		76,670
Transaction costs		41,000		-
Changes in non-cash working capital:				
Prepaid expenses		(8,076)		15,000
Accounts payable and accrued liabilities		78,447		(33,959)
		(147,040)		(370,178)
CASH FLOWS USED IN INVESTING ACTIVITY				
Loan receivable advances		(416,003)		-
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from issuance of shares, net of share issue cost		-		344,410
Proceeds from exercise of warrants		357,272		-
Proceeds from exercise of options		100,000		-
Subscriptions received in advance		75,000		-
Loans payable proceeds		124,500		115,500
Loans payable repayments		(3,500)		(70,128)
		653,272		389,782
NET CHANGE IN CASH		90,229		19,604
CASH – beginning of period		887		6,623
CASH – end of period	$	91,116	$	26,227
Supplemental cash flow information				
Common shares issued on conversion of convertible promissory notes	$	225,363	$	-
Common shares issued on conversion of RSUs		175,000		-
Common shares issued for debt settlement		151,650		76,792

(The accompanying notes are an integral part of these condensed interim financial statements)

1. Nature of Operations and Going Concern

Goat Industries Ltd. (the **"**Company" or "Goat") is an investment holding firm. On September 11, 2024, the Company adopted a revised investment policy whereby the Company's investments are not limited to any one sector. The Company was formerly focused on making investments in the functional foods, plant-based proteins, and health and wellness space as well as the mining industry. The Company was formed on September 22, 2020, under the Business Corporations Act in the Province of British Columbia, Canada. On September 12, 2022, the Company changed its name from Billy Goat Brands Ltd. to Goat Industries Ltd. The head office, registered address, and records office of the Company are located at 2200 - 885 West Georgia Street, Vancouver, BC, V6C 3E8.

These condensed interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to continue its operation as a going concern for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. At September 30, 2025, the Company had not achieved profitable operations, had an accumulated deficit of $25,936,774 (December 31, 2024 - $25,231,531), working capital deficiency of $161,158 (December 31, 2024 - $606,331), and expects to incur further losses in the development of its business. These material uncertainties cast significant doubt about the Company's ability to continue as a going concern. These condensed interim financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. Such adjustments could be material.

Although the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will continue to obtain the additional financial resources necessary and/or achieve profitability or positive cash flows from its future operations. If the Company is unable to obtain adequate additional financing, the Company would be required to curtail its planned operations.

On September 25, 2025, the Company entered into a share exchange agreement to acquire (the "1509BC Transaction") all of the issued and outstanding securities of 1509467 B.C. Ltd. ("1509BC") from the securityholders of 1509BC in exchange for an aggregate of 54,322,500 common shares in the capital of the Company. 46,822,500 of the common shares issued (the "Escrowed Shares") will be subject to a voluntary escrow whereby such shares will be released as follows: 25% of the Escrowed Shares released 4 months and 1 day after the closing date; and 18.75% of the Escrowed Shares released 7, 10, 13 and 16 months after the closing date.

50% of the Escrowed Shares shall be eligible for earlier release in the event that 1509BC books annual revenues of USD$10,000,000 and the remaining 50% of the Escrowed Shares shall be eligible for earlier release in the event that 1509BC books annual revenues of USD$20,000,000.

On October 14, 2025, the Company entered into a share exchange agreement to acquire (the "Vroom Transaction") all of the issued and outstanding securities of Veroom, Inc. ("Vroom") from the securityholders of Vroom in exchange for an aggregate of 15,677,500 common shares in the capital of the Company and 62,710,000 common share purchase warrants exercisable at a price of $0.45 for a period of five years from the date of issuance (the "Performance Warrants"). The common shares issued (the "Escrowed Shares") will be subject to a voluntary escrow whereby such shares will be released as follows: 25% of the Escrowed Shares released 4 months and 1 day after the closing date; and 18.75% of the Escrowed Shares released 7, 10, 13 and 16 months after the closing date.

50% of the Escrowed Shares shall be eligible for earlier release in the event that 1509BC books annual revenues of USD$10,000,000 and the remaining 50% of the Escrowed Shares shall be eligible for earlier release in the event that 1509BC books annual revenues of USD$20,000,000. 50% percent of the Performance Warrants will vest and become exercisable upon 1509BC booking annual revenues of USD$10,000,000 and the remaining 50% of the Performance Warrants will vest and become exercisable upon 1509BC booking annual revenues of USD$20,000,000.

The 1509 Transaction and the Vroom Transaction will not constitute a fundamental change or change of business, within the meaning of the policies of the CSE, however, as the 1509 Transaction and the Vroom Transaction will result in the Company issuing more than 100% of the current issued and outstanding Company Shares, shareholder approval will be required pursuant to CSE Policy 4 (the "Shareholder Approval").

1. Nature of Operations and Going Concern (continued)

Completion of the 1509 Transaction is subject to, among other things, (i) receipt of all necessary regulatory approvals, including, as applicable, all required filings with the Canadian Securities Exchange ("CSE"); (ii) completion of the Vroom Transaction; (iii) the Shareholder Approval (defined above); and (iv) completion of an equity financing by the Company of a minimum of $2,000,000 and up to $6,000,000 through the sale of units of the Company, at a price of $0.30 per unit, with each unit being comprised of one Company Share and one half of one Company Share purchase warrant, with each whole warrant exercisable at a price of $0.45 for a period of two years. As of the date of these financial statements, the 1509 Transaction had not closed.

Completion of the Vroom Transaction is subject to, among other things, (i) receipt of all necessary regulatory approvals, including, as applicable, all required filings with the Canadian Securities Exchange ("CSE"); (ii) completion of the Vroom Transaction; (iii) the Shareholder Approval (defined above); and (iv) completion of an equity financing by the Company of a minimum of $2,000,000 and up to $6,000,000 through the sale of units of the Company, at a price of $0.30 per unit, with each unit being comprised of one Company Share and one half of one Company Share purchase warrant, with each whole warrant exercisable at a price of $0.45 for a period of two years. As of the date of these financial statements, the Vroom Transaction had not closed.

1509BC and Vroom are known in the market as BETSource. The business of BETSource is focused on the global sports betting market, most directly in the US$40B+ North American Market, including the 500+ tribal casino markets. 1509BC is the owner of certain technologies and US licenses (the "Technology and Licenses") that enable casinos, sports books and sports book platforms to have a distinctive advantage by using a combination of content recognition and AI enabling personalization. This includes a combination of live sports content distribution rights intertwined with unique marketing and advertising approaches for the casino and/or sports book. Vroom is a sales and marketing business that activates a combination of live sports rights within casinos and sports books and is responsible for ensuring that the Technology and Licenses penetrate the market effectively.

2. Basis of Presentation

a) Statement of Compliance and Presentation

These condensed interim financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB have been condensed or omitted and therefore, these interim financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2024.

These condensed interim financial statements have been prepared on a historical cost basis, except for certain financial instruments, which have been measured at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

These condensed interim financial statements were approved and authorized for issue on December 1, 2025 by the directors of the Company.

b) Functional and Presentation Currency

The presentation and functional currency of the Company is the Canadian dollar. All amounts in these condensed interim financial statements are expressed in Canadian dollars, unless otherwise indicated.

c) Significant Accounting Judgments and Estimates

The preparation of these condensed interim financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed interim financial statements and reported amounts of expenses during the reporting period.

2. Basis of Presentation (continued)

a) Significant Accounting Judgments and Estimates (continued)

Actual outcomes could differ from these estimates. Estimates and assumptions are pervasive throughout the condensed interim financial statements and are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, and future periods impacted.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

i. Going concern

The assessment of whether the going concern assumption is appropriate requires management to consider all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. The Company is aware that material uncertainties exist related to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern.

ii. Investment entity

Management has applied judgment in determining whether the Company meets the criteria required under IFRS 10, in order to be classified as an investment entity. Management has applied the following typical characteristics of an investment entity: a) obtains funds from one or more investors for the purpose of providing those investor(s) with investment management services; b) commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and c) measures and evaluates the performance of substantially all of its investments on a fair value basis. An investment entity shall not consolidate its subsidiaries or apply IFRS 3 (business combination) when it obtains control of another entity.

iii. Investments

Where the fair values of investments in private companies recorded on the statements of financial position cannot be derived from active markets, they are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data is not available, judgment is required to establish fair value.

iv. Loans receivable

The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.

v. Share-based compensation

The Company uses the Black-Scholes option pricing model for valuation of share-based compensation. Option pricing models require the input of subjective assumptions including expected price volatility, interest rate and forfeiture rate. Changes in the input assumptions can materially affect the fair value estimate and the Company's earnings and equity reserves.

2. Basis of Presentation (continued)

a) Significant Accounting Judgments and Estimates (continued)

vi. Non-monetary transactions

Shares and warrants issued for consideration other than cash are valued at the fair value of assets received or services rendered. If the fair value of assets received or services rendered cannot be reliably measured, shares and warrants issued for consideration will be valued at the quoted market price or estimated using the Black-Scholes option pricing model at the date of issuance.

vii. Impairment of investments

Judgment is required in determining whether investments have indicators of impairment. Determining the amount of impairment of investments requires an estimation of the recoverable amount, which is defined as the higher of fair value less the cost of disposal or value in use. Many factors used in assessing recoverable amounts are outside of the control of management and it is reasonably likely that assumptions and estimates will change from period to period. These changes may result in future impairments.

viii. Fair value of investments and derivatives

The Company reviews its investments and records their fair value at each financial statement reporting date. For investments in public companies, fair value is determined based on the quoted market price. For investments in private companies, certain subjective measures, including recent share transactions, prices for comparable entities, review of cash flow projections and the investee's prospects, financial ratios and discounted cash flows are techniques used to determine fair value. Where possible, the Company uses inputs obtained from observable market data for its valuation models. However, if observable market data is not available, the Company uses judgment to determine fair value.

3. Material Accounting Policies

In preparing these condensed interim financial statements, the material accounting policies and the significant judgments made by management in applying the Company's material accounting policies and key sources of estimation uncertainty were the same as those that applied to the Company's audited financial statements for the year ended December 31, 2024.

4. Investments

Investment continuity schedule as at September 30, 2025 and December 31, 2024 is presented as follows:

	Total
Balance, December 31, 2023	**271,880**
Fair value change	(271,879)
Balance, December 31, 2024 and September 30, 2025	**$ 1**

4. Investments (continued)

At September 30, 2025 and December 31, 2024, the Company held the following investments:

	Number of Shares		Cost		Fair Value
Private Companies					
1000288601 Ontario Inc. (Ekosolve)	**45,000,000**		1,350,000		-
Evanesce Packaging Solutions Inc.	**72,918**		271,880		1
Funguys Beverage Inc.	**100**		2,535,132		-
Kojo Pet Performance Inc.	**25,000,000**		1,035,000		-
Sophie's Kitchen, Inc.	**4,749,425**		5,884,606		-
Vegetarian Butcher Inc.	**1,842,105**	$	350,000	$	-
		$	**11,426,618**	**$**	**1**

At September 30, 2025 and December 31, 2024, the Company held the following investment assets:

		Cost		Fair Value
Assets held				
Smithers Mining Claims	$	562,500	$	-
Cirn Mining Claims	$	800,000	$	-
Donovan Mining Claims	$	800,000	$	-
	$	**2,162,500**	**$**	**-**

Funguys Beverage Inc.

On February 8, 2021, the Company acquired all of the issued and outstanding common shares of Funguys Beverage Inc. ("Funguys") for 219,956 common shares of the Company at a price of $10 per share and 109,978 warrants at an exercise price of $25, exercisable for a period of twenty-four months following the closing date. The fair value of the warrants was estimated to be $335,572 using the Black-Scholes option pricing model with the following assumptions: term - two years, expected volatility - 100%, risk-free rate - 0.18%, and expected dividends – zero. During the year ended December 31, 2022, the Company impaired Funguys investment and recognized a fair value loss of $1,561,279. The impairment was recognized as the Company estimated realization of the value of Funguys investment was unforeseeable due to its continued lack of performance and the Company does not intend to support these types of investments due to changes in the sector of focus from investments towards mining exploration. As at September 30, 2025, the fair value of the investment in Funguys was determined to be $Nil (December 31, 2024 - $Nil).

Sophie's Kitchen, Inc.

On February 8, 2021, the Company entered into a loan agreement where the Company agreed to loan CAD$614,673 (US$500,000) at the rate of 6% interest per annum with a maturity date of June 30, 2022 to Sophie's Kitchen, Inc. ("Sophie's Kitchen"). The loan was to be used for general working capital purposes in connection with the development and expansion of the existing operations of Sophie's Kitchen.

On March 15, 2021, the Company entered into a credit facility agreement with Sophie's Kitchen to establish a credit facility in the principal amount of US$3,000,000 (the "SF Credit Facility") at the rate of 6% interest per annum with a maturity date twelve months after closing. The SF Credit Facility permits short term loans for general working capital purposes of Sophie's Kitchen. The maximum monthly draw from the SF Credit Facility is US$500,000. The Company issued 15,000 finders' common shares in connection with the SF Credit Facility at a value of $25 per share.

4. Investments (continued)

Sophie's Kitchen, Inc. (continued)

The Company received share purchase warrants entitling the Company to acquire additional common shares of Sophie's Kitchen with a value of US$1,500,000 based on a twenty percent discount from the post-subscription valuation of Sophie's Kitchen immediately prior to a public listing of Sophie's Kitchen. These warrants can be converted to Sophie's Kitchen common equity at any time prior to the warrant maturity date of March 15, 2031. In connection to the warrants, the Company originally recognized the value of the warrants for $1,250,000. As at September 30, 2025, the fair value of the warrants is $Nil (December 31, 2024 - $Nil).

The Company also had a share subscription option within the SF Credit Facility at a predetermined valuation, to acquire additional common shares of Sophie's Kitchen with a value of US$2,400,000, less the accrued interest and an in-kind investment in the amount of US$218,500. Whereby the US$218,500 represented an outstanding liability of Sophie's Kitchen that would be settled through the issuance of the Company's common shares. This US$2,400,000 subscription option expired on March 31, 2022, the maturity date of the SF Credit Facility.

Sophie's Kitchen had the option to cause the Company to acquire additional Sophie's Kitchen shares valued at US$2,000,000, less accrued interest ("Sophie's Kitchen Option"). The consideration paid by the Company for the Sophie's Kitchen Option was in the form of common shares of the Company based on a price of $25 per share. In connection with the Sophie's Kitchen Option, the Company originally recognized a derivative liability for $976,000. At December 31, 2022, the derivative liability was extinguished as the option expired unexercised on March 15, 2022.

On July 7, 2021, the Company acquired 1,531,751 Sophie's Kitchen shares. In consideration for the Sophie's Kitchen shares acquired, the Company made cash payments of $1,212,524 and issued 27,093 common shares. Of the 27,093 common shares, 10,925 common shares were issued in connection to the in-kind investment for the settlement of US$218,500 (described above). The cost of the investment in Sophie's Kitchen was valued at $1,889,850 at December 31, 2021. At December 31, 2021, the Company recognized a gain on change of fair value of $133,016 resulting in an investment in Sophie's Kitchen to $2,022,866 at year end.

On March 15, 2022, total drawdowns of $3,994,756 were made as per the SF Credit Facility, which includes interest accrual of $153,856. On March 15, 2022, the principal and accrued interest on the credit facility were automatically converted into 3,217,674 common shares of Sophie's Kitchen. During the year ended December 31, 2022, the Company impaired Sophie's Kitchen investment and recognized a fair value loss of $7,112,622. The impairment was recognized as the Company estimated realization of the value of Sophie's Kitchen investment was unforeseeable due to its continued lack of performance and the Company does not intend to support these types of investments due to changes in the sector of focus from investments towards mining exploration. As at September 30, 2025, the fair value of Sophie's Kitchen investment in common shares is $Nil (December 31, 2024 - $Nil).

Vegetarian Butcher Inc.

On February 10, 2021, the Company acquired 1,842,105 common shares of The Vegetarian Butcher Inc. ("Vegetarian"), for a 12.4% ownership of Vegetarian, at $0.19 per share for a total of $350,000. The Company issued 20,000 finders' common shares in connection with the purchase of Vegetarian common shares at a value of $25 per share. During the year ended December 31, 2022, the Company impaired Vegetarian Butcher investments and recognized a fair value loss of $350,000. The impairment was recognized as the Company estimated realization of the value of Vegetarian Butcher investment was unforeseeable due to its continued lack of performance and the Company does not intend to support these types of investments due to changes in the sector of focus from investments towards mining exploration. As at September 30, 2025, fair value of the investment is $Nil (December 31, 2024 - $Nil).

4. Investments (continued)

Evanesce Packaging Solutions Inc.

On August 13, 2021, the Company subscribed for 41,667 units at $3.60 per unit of Evanesce Packaging Solutions Inc. ("Evanesce"). Each unit consists of one common share of Evanesce and one-half common share purchase warrant. Each whole warrant entitles the Company to purchase one additional common share for a period of two years at a price of $3.90 if exercised in the first twelve months following issuance or $4.80 if exercised after twelve months after the issuance. The fair value of the units was allocated to the shares and warrants using the Black-Scholes option pricing model with the inputs described above.

During the year ended December 31, 2022, the Company acquired 31,251 common shares in Evanesce through the full exercise of 20,834 warrants outstanding at an exercise price of $3.90 for cash consideration of $121,879. In connection with the early exercise, the Company received an additional 10,417 incentive warrants in Evanesce. During the year ended December 31, 2024, the Company impaired Evanesce investment and recognized a fair value loss of $271,879. The impairment was recognized as the Company estimated realization of the value was unforeseeable based on available financial and operational information from the investee, as well as market conditions affecting its viability. As at September 30, 2025, the fair value of investment in Evanesce is $1 (December 31, 2024 - $1).

Kojo Pet Performance Inc.

On August 16, 2022, the Company completed the acquisition of Kojo Pet Performance Inc. ("Kojo") in consideration of 250,000 common shares of the Company issued at a fair value share price of $3.50 per share to the existing shareholders of Kojo. Furthermore, the Vendors are eligible to earn up to an additional 300,000 Consideration Shares upon the realization of the following performance milestones by Kojo within 36 months from the date of closing:

40,000 Consideration Shares upon Kojo entering into a letter of intent with a pet food distributor;
70,000 Consideration Shares upon Kojo signing a third retail store for North American retail distribution;
30,000 Consideration Shares upon Kojo generating $250,000 in annual revenue;
60,000 Consideration Shares upon Kojo generating $500,000 in annual revenue; and
100,000 Consideration Shares upon Kojo generating $1,000,000 in annual revenue.

During the year ended December 31, 2022, the Company impaired Kojo investment and recognized a fair value loss of $1,035,000. The impairment was recognized as the Company estimated realization of the value of Kojo investment was unforeseeable due to its lack of performance, lack of working capital, and the Company does not intend to support these types of investments due to changes in the sector of focus from investments towards mining exploration. As at September 30, 2025, the fair value of Kojo investment is $Nil (December 31, 2024 - $Nil).

1000288601 Ontario Inc. (Ekosolve Ltd.)

On September 29, 2022, the Company completed its acquisition of 1000288601 Ontario Inc. ("Ontario Co"). In consideration for the transaction, the Company issued 450,000 common shares at a fair value share price of $3.00 per share to the former shareholders of Ontario Co. for a total consideration of $1,350,000. Upon acquisition, Goat controls a license for use of lithium solvent extraction technology in Canada from Australia-based Ekosolve Ltd. ("Ekosolve"). During the year ended December 31, 2023, the Company impaired Ontario Co investment and recognized a fair value loss of $1,350,000. The impairment was recognized as the Company estimated realization of the value of Ontario Co investment was unforeseeable due to its lack of performance and lack of working capital. As at September 30, 2025, the fair value of the Ontario Co investment is $Nil (December 31, 2024 - $Nil).

4. Investments (continued)

Investment in mining claims

On November 21, 2022, the Company issued 375,000 common shares with a fair value of $562,500 to acquire 100% of a claim block (the "Claim Block") in the vicinity of American Eagle Gold Corp.'s ("American Eagle Gold") (TSXV: AE) copper mineralized NAK discovery (the "NAK Copper Discovery"), located approximately 85 kilometres from Smithers, British Columbia. During the year ended December 31, 2023, the Claim Block was subject to automatic forfeiture as a result of a lack of exploration and development work registered on the Claim Block.

Upon the forfeiture of the Claim Block, the Company impaired the investment to $Nil and recognized a fair value loss of $562,500.

On March 24, 2023, the Company completed an asset purchase agreement with Donovan Explorations Ltd. ("Donovan Vendors") and Cirn Crypto-Monnais Corp.("Cirn Vendors") to acquire certain mineral claims located in Quebec (the "Donovan Claims" and the "Cirn Claims"). Pursuant to the terms of the Agreement, the Company acquired a 100% interest the Donovan Claims and Cirn Claims in consideration for issuing 400,000 common shares of the Company to the Donovan Vendors and 400,000 common shares of the Company to the Cirn Vendors respectively, at a fair value of $2.00 per share, representing an aggregate value of $1,600,000 for the acquisitions. During the year ended December 31, 2023, the Company impaired the Donovan Claims and the Cirn Claims and recognized a fair value loss of $1,600,000. The impairment was recognized as the Company does not intend to allocate resources to conduct substantive exploration and evaluation activities.

On April 3, 2024, the Company entered into an option agreement (the "Option Agreement") with an arm's length party (the "Purchaser"). The Option Agreement provides the Purchaser the option to acquire up to a 100% interest in the Donovan and Cirn Claims for the following considerations:

- Upon exercise of the Option Agreement by the Purchaser, $10,000 and shares of the Purchaser representing 10% of the issued and outstanding shares.
- Upon final execution of the Option Agreement by the Company and the Purchaser, $10,000 and shares of the Purchaser representing 10% of the issued and outstanding shares.

5. Loan Receivable

In connection with the 1509 Transction (Note 1), the Company will advance up to USD$300,000 to 1509BC pursuant to a promissory note dated August 28, 2025. The promissory note is unsecured, bears interest at 10% per annum, and is repayable by 1509BC on: (i) the closing the 1509 Transaction (ii) October 31, 2025; (iii) upon termination of the 1509 Transaction by 1509BC. 1509BC has also agreed to pay a facilitation fee of $5,000 to the Company upon full repayment of the promissory note.

During the period ended September 30, 2025, the Company advanced USD$296,000 (2024 - USD$Nil) under the promissory note. During the period ended September 30, 2025, the Company recognized interest income of $3,569 (2024 - $Nil). As at September 30, 2025, the total loan receivable balance is $415,613 (December 31, 2024 - $Nil).

6. Loan Payable

During the period ended September 30, 2025, the Company received $124,500 (2024 - $115,500) in loans from arm's length parties and repaid $2,500 (2024 - $70,128) to loan holders.

During the period ended September 30, 2025, the Company extinguished $Nil (2024 - $316,156) of loans payable bearing interest at 10% per annum in exchange for the issuance of $Nil (2024 - $316,156) of convertible promissory notes (Note 7).

As at September 30, 2025, outstanding loans consist of $166,949 (December 31, 2024 - $25,000) of which $126,949 (December 31, 2024 – $Nil) bears interest at 10% per annum, due on demand and are unsecured. All other loans bear no interest rate, are due on demand and are unsecured.

7. Convertible Promissory Notes

During the year ended December 31, 2024, the Company issued $316,156 of convertible promissory notes in exchange for the extinguishment of $316,156 of loans payable bearing interest at 10% per annum. Each convertible promissory note is convertible into units consisting of one common share and one common share purchase warrant at a price of $0.095. Each common share purchase warrant has a term of 24 months from the date of issuance and entitles the holder to purchase one common share at a price of $0.15. The convertible promissory notes are unsecured, non-interest bearing and mature on June 28, 2026. On initial recognition, the Company bifurcated $54,870 to equity and $261,286 to the carrying value of the convertible promissory notes, which will be accreted to $316,156 over the term of the convertible promissory notes. During the period ended September 30, 2025, the Company recognized interest expense of $1,349 (2024 - $5,589). The effective interest rate of the debentures is 10%.

On January 23, 2025, the Company issued 2,717,959 units at a price of $0.095 per unit pursuant to the conversion of $258,206 of convertible promissory notes. As a result, the Company reallocated $225,363 from the carrying value and $44,813 from equity portion of convertible promissory notes to share capital.

8. Share Capital

Authorized

Unlimited common shares without par value.

Escrow Shares

At September 30, 2025, there were Nil (December 31, 2024 – Nil) shares held in escrow. 25,247 shares were released on each of the following dates: March 16, 2024 and September 16, 2024.

Issued Common Shares

During the period ended September 30, 2025, the Company had the following transactions that resulted in the issuance of its common shares:

On January 23, 2025, the Company issued 2,717,959 units (each a "Unit") at a price of $0.095 per unit pursuant to the conversion of $258,206 of convertible promissory notes (Note 7). Each Unit is comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"), with each Warrant exercisable into one common share for a period of two (2) years at a price of $0.15.

On February 10, 2025, the Company settled debt in an aggregate amount of $150,000 by issuing an aggregate of 600,000 units (each a "Unit") with a fair value of $237,000, recognizing a loss on debt settlement of $87,000. Each Unit is comprised of one common share in the capital of the Company (a "Common Share) and one common share purchase warrant (a "Warrant"). Each Warrant is exercisable for one Common Share at a price of $0.325 per share until February 10, 2027, pursuant to applicable securities laws.

On April 21, 2025, the Company issued 10,530 common shares upon exercise of 10,530 warrants for total proceeds of $1,580.

On July 11, 2025, the Company issued 500,000 common shares upon conversion of 500,000 RSUs for no additional consideration.

On August 1, 2025, the Company issued 250,000 common shares upon exercise of 250,000 warrants for total proceeds of $37,500.

On August 6, 2025, the Company issued 800,000 common shares upon exercise of 800,000 stock options for total proceeds of $100,000 and 643,852 common shares upon exercise of 643,852 warrants for total proceeds of $96,578.

8. Share Capital (continued)

Issued Common Shares (continued)

On August 14, 2025, the Company issued 200,000 common shares upon exercise of 200,000 warrants for total proceeds of $30,000.

On August 27, 2025, the Company issued 111,112 common shares upon exercise of 111,112 warrants for total proceeds of $16,667.

On September 2, 2025, the Company issued 866,316 common shares upon exercise of 866,316 warrants for total proceeds of $129,947.

On September 15, 2025, the Company issued 100,000 common shares upon exercise of 100,000 warrants for total proceeds of $15,000.

On September 25, 2025, the Company issued 200,000 common shares upon exercise of 200,000 warrants for total proceeds of $30,000.

During the period ended September 30, 2025, the Company received $75,000 for subscriptions for a private placement that closed on October 6, 2025 at a price of $0.30 per unit. Each unit consists of one common share and one-half of one transferable common share purchase warrant. Each whole warrant will entitle the holder to purchase, for a period of 2 years from the date of issue, one additional common share of the Issuer at an exercise price of $0.45 per share.

During the period ended September 30, 2024, the Company had the following transactions that resulted in the issuance of its common shares:

On March 21, 2024, the Company issued 320,000 units (each a "Unit") at a price of $0.109 per unit to settle outstanding indebtedness in the aggregate amount of $34,880 pursuant to debt settlement agreements with certain creditors of the Company. Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"), with each Warrant exercisable for a period of two (2) years at a price of $0.15 per Warrant.

On April 9, 2024, the Company issued 465,689 units (each a "Unit") at a price of $0.09 per unit to settle outstanding indebtedness in the aggregate amount of $41,912.01 pursuant to debt settlement agreements with certain creditors of the Company. Each Unit will be comprised one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"), with each Warrant exercisable for a period of two (2) years at a price of C$0.15 per Warrant.

On June 28, 2024, the Company issued 2,021,056 units at a price of $0.095 per unit for gross proceeds of $192,000 pursuant to a non-brokered private placement. Each unit is comprised of one common share in the capital of the Company and one common share purchase warrant. Each common share purchase warrant will entitle the holder thereof to acquire one common share at a price of $0.15 for a period of two years from the date of issuance. The Company paid finder's fees of $10,640 in cash in relation to the private placement.

On July 4, 2024, the Company issued 460,000 units (each a "Unit") at a price of $0.095 per unit pursuant to the conversion of $43,700 of convertible promissory notes (Note 7). Each Unit is comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"), with each Warrant exercisable into one common share for a period of two (2) years at a price of $0.15.

On September 10, 2024, the Company issued 150,000 units (each a "Unit") at a price of $0.095 per unit pursuant to the conversion of $14,250 of convertible promissory notes (Note 7). Each Unit is comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"), with each Warrant exercisable into one common share for a period of two (2) years at a price of $0.15.

8. Share Capital (continued)

Issued Common Shares (continued)

On September 10, 2024, the Company issued 1,366,316 units (each a "Unit") at a price of $0.095 per unit for gross proceeds of $129,800 pursuant to a non-brokered private placement. Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant. Each common share purchase warrant will entitle the holder thereof to acquire one common share at a price of $0.15 for a period of two years from the date of issuance.

On September 23, 2024, the Company issued 350,000 units (each a "Unit") at a price of $0.095 per unit for gross proceeds of $33,250 pursuant to a non-brokered private placement. Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant. Each common share purchase warrant will entitle the holder thereof to acquire one common share at a price of $0.15 for a period of two years from the date of issuance.

Stock options – Directors, Officers, Employees and Consultants

During the year ended December 31, 2024, the Company adopted an Omnibus Equity Incentive Plan and may, from time-to-time, grant to directors, officers, employees and consultants of the Company, options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 20% of the issued and outstanding common shares, exercisable for a period of up to ten years from the date of grant. Shareholder approval of the Omnibus Equity Incentive Plan was received at the annual general and special meeting of shareholders held on October 10, 2024.

The continuity of stock options granted to directors, officers, employees and consultants of the Company for the period ended September 30, 2025 is as follows:

Grant Date	Expiry date	Number of options	Exercise price
		#	$
August 1, 2025	August 1, 2027	2,400,000	0.235
Balance at September 30, 2025		**2,400,000**	**0.235**

	Number of options	Weighted average exercise price
	#	$
Balance at December 31, 2023	**33,625**	**22.96**
Options granted	800,000	0.125
Options cancelled	(33,625)	22.96
Balance at December 31, 2024	**800,000**	**0.125**
Options granted	2,400,000	0.235
Options exercised	(800,000)	0.125
Balance at September 30, 2025	**2,400,000**	**0.235**
Vested and Exercisable	**2,400,000**	**0.235**

As at September 30, 2025, the stock options have a weighted average remaining contractual life of 1.84 years (December 31, 2024 – 4.38 years).

On May 17, 2024, the Company granted 800,000 stock options to consultants of the Company, vesting 100% on the grant date with an exercise price of $0.125 and an expiry date of May 17, 2029. The fair value of the stock options was estimated to be $92,419. The Black-Scholes option pricing model was used with the following assumptions: term – 5 years, expected volatility – 155%, risk free rate – 3.60%, and expected dividends – zero. During the period ended September 30, 2025, the Company recognized $Nil (2025 - $76,670) share based compensation.

8. Share Capital (continued)

Stock options – Directors, Officers, Employees and Consultants (continued)

On August 1, 2025, the Company granted 2,400,000 stock options to consultants of the Company, vesting 100% on the grant date with an exercise price of $0.235 and an expiry date of August 1, 2027. The fair value of the stock options was estimated to be $419,795. The Black-Scholes option pricing model was used with the following assumptions: term – 2 years, expected volatility – 158%, risk free rate – 2.68%, and expected dividends – zero. During the period ended September 30, 2025, the Company recognized $419,795 (2024 - $Nil) share based compensation.

Restricted Share Units

During the year ended December 31, 2024, the Company adopted an Omnibus Equity Incentive Plan and may, from time-to-time, grant to directors, officers, employees and consultants of the Company, restricted share units, provided that the number of common shares reserved for issuance will not exceed 20% of the issued and outstanding common shares. Shareholder approval of the Omnibus Equity Incentive Plan was received at the annual general and special meeting of shareholders held on October 10, 2024.

Pursuant to the Omnibus Equity Incentive Plan, if outstanding restricted share units ("RSU") are converted, or expire, and/or the number of issued and outstanding common shares of the Company increases, then the options available to grant under the plan increase proportionately. Vesting of RSUs is at the discretion of the Board of Directors at the time the RSUs are granted. Participants in the RSU plan may elect to redeem their share units by the Company issuing the participant one common share for each whole vested share unit.

On February 7, 2025, the Company granted 500,000 RSUs to consultants of the Company expiring February 7, 2027. The RSUs were fully vested February 7, 2025. The fair value of the RSUs was $175,000 calculated based on the Company's share price on the grant date. During the period ended September 30, 2025, the Company recognized $175,000 (2024 - $Nil) share based compensation.

During the period ended September 30, 2025, a total of 500,000 (2024 – Nil) RSUs were converted.

During the period ended September 30, 2025, a total of Nil (2024 – 2,000) RSUs were cancelled.

The following table summarizes information on RSUs outstanding and exercisable at September 30, 2025:

	Number of RSU	Weighted average conversion price
		$
Balance at December 31, 2023	**2,000**	**25**
RSUs cancelled	(2,000)	25
Balance at December 31, 2024	**-**	**-**
RSUs granted	500,000	0.35
RSUs converted	(500,000)	(0.35)
Balance at September 30, 2025	**-**	**-**
Vested and Exercisable	**-**	**-**

Finders' Warrants

The continuity of finders' warrants for the period ended September 30, 2025 is as follows:

	Number of warrants	Weighted average exercise price
		$
Balance at December 31, 2023	**-**	**-**
Finders' warrants issued	112,000	0.15
Balance at December 31, 2024 and September 30, 2025	**112,000**	**0.15**

8. Share Capital (continued)

Finders' Warrants (continued)

On June 28, 2024, the Company issued 112,000 finders' warrants with an exercise price of $0.15 expiring on June 28, 2026, in connection with the completed private placement. The fair value of the finder's warrants was estimated to be $18,131 using the Black-Scholes option pricing model with the following assumptions: term - 2 years; expected volatility - 192%; risk-free rate – 3.86%; and expected dividends - zero.

Warrants

The continuity of warrants for the period ended September 30, 2025 is as follows:

Grant Date	Expiry date	Number of warrants	Conversion price
		#	$
December 4, 2021	December 4, 2025	191,750	10
November 15, 2022	June 14, 2027	161,500	5
March 21, 2024	March 21, 2026	320,000	0.15
April 9, 2024	April 9, 2026	354,577	0.15
June 28, 2024	June 28, 2026	1,610,526	0.15
July 4, 2024	July 4, 2026	460,000	0.15
September 10, 2024	September 10, 2026	750,000	0.15
January 23, 2025	January 23, 2027	1,974,107	0.15
February 10, 2025	February 10, 2027	600,000	0.325
Balance at September 30, 2025		**6,422,460**	**0.58**

	Number of warrants	Weighted average exercise price
		$
Balance at December 31, 2023	**353,250**	**8**
Warrants issued	5,133,061	0.15
Balance at December 31, 2024	**5,486,311**	**0.64**
Warrants exercised	(2,381,810)	0.15
Warrants issued	3,317,959	0.18
Balance at September 30, 2025	**6,422,460**	**0.58**

Special Warrants

The continuity of special warrants for the period ended September 30, 2025 is as follows:

	Number of warrants	Weighted average exercise price
		$
Balance at December 31, 2023 and December 31, 2024	86,000	2.5
Special Warrants expired	(86,000)	2.5
Balance at September 30, 2025	**-**	**-**

On February 2, 2023, the Company issued 86,000 special warrants at a price of $2.5 per warrant for gross proceeds of $215,000 pursuant to the closure of a non-brokered private placement on special warrants. Each Special Warrant entitles the holder to acquire one unit of the Issuer. Each Special Warrant will entitle the holder thereof to acquire one Unit at a price of $2.5 per Unit for a period of two years from issuance. Each Unit is comprised of one common share in the capital of the Company and one transferable common share purchase warrant. Each warrant will entitle the holder thereof to acquire one additional share of the Company at a price of $5 per Share until the date of expiration of the Conversion Warrant, which is two years following the issuance date. The Company recorded $215,000 in warrant reserve for the issuance of special warrants. During the period ended September 30, 2025, 86,000 (2024 – Nil) special warrants expired and the Company reclassified $215,000 from warrant reserve to deficit.

9. Related Party Disclosures

The Company's related parties consist of its key management personnel, including its directors and officers.

During the normal course of business, the Company entered into transactions with its related parties at normal market prices and on normal commercial terms.

	For the period ended September 30, 2025	For the period ended September 30, 2024
	$	$
Management fees paid/accrued to companies controlled by officers of the Company	12,600	9,450
Management fees paid/accrued to former officers of the Company	3,150	-
Management fees paid/accrued to companies controlled by directors of the Company	1,050	9,450
Management fees paid/accrued to directors of the Company	9,750	17,850
	26,550	**36,750**

As at September 30, 2025, $58,400 is due to related parties (December 31, 2024 - $68,325) and included in the accounts payable and accrued liabilities. All balances are unsecured, non-interest bearing, and are due on demand.

10. Financial Instruments and Risk Management

a) Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles most of its financial obligations with cash. The ability to do this relies on the Company raising equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs. The Company is exposed to liquidity risk.

As at September 30, 2025, the Company had a cash balance of $91,116 (December 31, 2024 - $887) to settle current liabilities of $675,963 (December 31, 2024 - $607,218), which are due within 12 months.

b) Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and the loan receivable.

c) Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. Interest rate risk consists of two components:

i. To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk; and

ii. To the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

Current financial assets and financial liabilities are generally not exposed to interest rate cash flow risk due to their short-term nature and maturity.

d) Currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange. The Company has foreign currency exposure on the investment in Sophie's Kitchen and the loan receivable due to the difference in currencies. The Company has not entered into any foreign currency contracts to mitigate this risk.

10. Financial Instruments and Risk Management (continued)

e) Price risk is the risk of potential losses to the Company's earnings due to movements in individual equity movements. As at September 30, 2025, the Company's investments of $1 are subject to fair value fluctuations. If the fair value of the Company's investments had a decrease or increase of 10% with all other variances held constant, the net loss and comprehensive loss for the period ended September 30, 2025 would be approximately $Nil higher or lower.

f) The Company's financial instruments consist of cash, loan receivable, investments, accounts payable and accrued liabilities, loans payable and convertible promissory notes. Financial instruments measured at fair value are classified into one of the three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of hierarchy are:

Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.
Level 3: Techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

Financial instruments classified as Level 1 - unadjusted quoted prices in active markets include cash.

The estimated fair value of cash and accounts payable and accrued liabilities are equal to their carrying values due to the short-term nature of these instruments. Investments are measured at fair value through profit and loss measured using Level 3 inputs.

The following is an analysis of the Company's financial assets and liabilities measured at fair value as at September 30, 2025 and December 31, 2024:

	As at September 30, 2025		
	Level 1	**Level 2**	**Level 3**
	$		**$**
Cash	91,116	-	-
Investments	-	-	1

	As at December 31, 2024		
	Level 1	**Level 2**	**Level 3**
	$		**$**
Cash	887	-	-
Investments	-	-	1

g) Capital management

The Company manages its capital structure and makes adjustments based on the funds available to the Company, in order to meet its daily operating expenses. The Company may raise additional capital for additional cash required. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to identify and acquire new investment or business opportunities.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the period ended September 30, 2025 and the year ended December 31, 2024. The Company is not subject to externally imposed capital requirements.

11. Commitments

On August 16, 2022, the Company completed the acquisition of Kojo Pet Performance Inc. ("Kojo") in consideration of 250,000 common shares of the Company issued at a fair value share price of $3.5 per share to the existing shareholders of Kojo. Furthermore, the Vendors are eligible to earn up to an additional 300,000 Consideration Shares upon the realization of the following performance milestones by Kojo within 36 months from the date of closing:

- 40,000 Consideration Shares upon Kojo entering into a letter of intent with a pet food distributor (issued);
- 70,000 Consideration Shares upon Kojo signing a third retail store for North American retail distribution (not issued);
- 30,000 Consideration Shares upon Kojo generating $250,000 in annual revenue (not issued);
- 60,000 Consideration Shares upon Kojo generating $500,000 in annual revenue (not issued); and
- 100,000 Consideration Shares upon Kojo generating $1,000,000 in annual revenue (not issued).

12. Subsequent Events

On October 6, 2025, the Company issued 6,730,666 units at a price of $0.30 per unit for gross proceeds of $2,019,200 pursuant to a non-brokered private placement. Each unit is comprised of one common share in the capital of the Company and one-half of one common share purchase warrant. Each whole common share purchase warrant will entitle the holder thereof to acquire one common share at a price of $0.45 for a period of two years from the date of issuance. The Company paid finder's fees to certain qualified non-related parties totaling $99,414 and 331,380 broker warrants (each a "Broker Warrant"). Each Broker Warrant entitles the holder to acquire one half of one common share of the Company at $0.45 for two years from the date of issue in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All securities issued will be subject to a statutory hold period of four (4) months and one (1) day from the date of issuance pursuant to applicable securities laws.

On October 8, 2025, the Company issued 237,000 common shares upon exercise of 237,000 warrants for total proceeds of $35,550.

On October 16, 2025, the Company issued 100,000 common shares upon exercise of 100,000 warrants for total proceeds of $15,000.

On October 22, 2025, the Company issued 195,526 common shares upon exercise of 195,526 warrants for total proceeds of $29,329.

On October 27, 2025, the Company issued 250,000 common shares upon exercise of 250,000 warrants for total proceeds of $37,500.

On October 30, 2025, the Company issued 800,000 common shares upon exercise of 800,000 warrants for total proceeds of $120,000.

On November 13, 2025, the Company issued 11,201,711 units at a price of $0.30 per unit for gross proceeds of $3,360,513 pursuant to a non-brokered private placement. Each unit is comprised of one common share in the capital of the Company and one-half of one common share purchase warrant. Each whole common share purchase warrant will entitle the holder thereof to acquire one common share at a price of $0.45 for a period of two years from the date of issuance. The Company paid finder's fees to certain qualified non-related parties totaling $64,869 and 216,230 broker warrants (each a "Broker Warrant"). Each Broker Warrant entitles the holder to acquire one half of one common share of the Company at $0.45 for two years from the date of issue in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All securities issued will be subject to a statutory hold period of four (4) months and one (1) day from the date of issuance pursuant to applicable securities laws.